Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Making a noteworthy insider sell on November 12, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex (NASDAQ:VERX), is reported in the latest ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

Jeffrey Westphal, 10% Owner at Vertex VERX, executed a substantial insider sell on November 14, according to an SEC filing. Vertex shares are trading up 0.43% at $50.8 at the time of this writing ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

But there was one company that kept at it. Fast-forward to today, and Vertex Pharmaceuticals is on the verge of gaining an FDA approval for suzetrigine (VX-548), a nonaddictive oral treatment that ...

Jeffrey Westphal, 10% Owner at Vertex (NASDAQ:VERX), executed a substantial insider sell on November 14, according to an SEC filing. What Happened: Westphal's recent move involves selling ...

Vertex Flashes A Surprise Buy Point As Non-Opioid Pain Drug Looms Vertex beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known ...